The Hyper IgE Syndrome and Mutations in TYK2  by Woellner, Cristina et al.
Immunity
CorrespondenceThe Hyper IgE Syndrome
and Mutations in TYK2The hyperimmunoglobulin E syndrome
(HIES) is a rare primary immunodefi-
ciency, characterized by the clinical
triad of recurrent staphylococcal skin
abscesses, recurrent respiratory-tract
infections, and serum IgE concen-
trations of >2000 IU/mL. Autosomal
dominant (AD) and autosomal reces-
sive (AR) forms have been described
(Grimbacher et al., 1999; Renner
et al., 2004). The AR-HIES variant in-
cludes, in addition to this HIES triad,
recurrent viral infections, extreme
eosinophilia, and neurological compli-
cations but no skeletal symptoms.
In the November 2006 issue of Im-
munity, Minegishi et al. (2006) reported
the first monogenetic defect in a single
patient, from consanguineous parents,
who was presented with some clinical
features of autosomal-recessive HIES.
The patient had a homozygous defect
in the receptor-associated cytoplas-
matic tyrosine kinase TYK2. However,
the authors did not report whether they
investigatedTYK2 in additional patients
with AR-HIES. Thus, it remains an open
questionwhetherTyk2deficiencymight
be a common cause of AR-HIES.
This prompted us to analyze TYK2
in a collection of patients with the
characteristic appearance of the auto-
somal-recessive HIES. All patients
participating in this study were con-
sented according to protocols ap-
proved by a local ethics-review board.
We screened a total of 15 autoso-
mal-recessive families with HIES
(seven of them from consanguineous
marriages including three unrelated
patients out of the initially six published
families; see Renner et al. [2004]) by
genotyping and linkage analysis. The
affected individuals in five families
were homozygous at marker D19S586
within 1 Mb of the TYK2 gene. Four ofthe five families had at least one un-
affected child, and in three of these
four, the genotype data were consis-
tentwithgenetic linkage to theTYK2 lo-
cus on chromosome 19. We subse-
quently performed sequence analysis
on the genomic DNA of one patient
from each of these five families, by us-
ing the primers for human TYK2 kindly
provided by Minegishi et al. (2006).
We did not find any mutation in the
coding regions of exons and the adja-
cent intronic sequences ofTYK2. How-
ever, we did not analyze the full intronic
regions and the promoter of the gene.
We conclude that Tyk2 deficiency is
most likely not a common cause of the
AR-HIES and suggest that human Tyk2
deficiency is a distinct disease entity
that is genetically and clinically different
from the previously published patients
with AR-HIES. This hypothesis is sup-
ported by atypical features in the clini-
cal history of the patient described
by Minegishi et al. (2006), such as
a BCG lymphadenitis and a non-Typhi
Salmonella infection. The susceptibility
to these certain viral and intracellular
bacterial infections may imply that hu-
man TYK2 deficiency is clinically and
pathophysiologically closely related to
patients with particular defects in the
interleukin-12-interferon axis as de-
scribed by Casanova and Abel (2004).
Therefore, it might be rewarding to
analyze TYK2 further in these cohorts
in addition to patients with AR-HIES.
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